This 2021 human study related Vitamin K2 status and statin usage:
“We examined the connection between statin exposure, coronary artery calcification (CAC), and vitamin K-dependent proteins (VKDPs) in patients with cardiovascular (CV) conditions. VKDPs measured in plasma included undercarboxylated (ucOC), and carboxylated osteocalcin (cOC).
CAC score (CACS) was determined by multislice computed tomography:
CACS was more pronounced in statin users compared to non-users. The same was also found among CVD patients and among controls. Both ucOC and ucOC / cOC ratio were significantly elevated in statin users, indicating vitamin K deficiency.
Our results are in agreement with existing evidence about positive associations between statins and vascular calcification. They enlighten possible mechanisms through which statins may enhance calcium accumulation in arterial wall, by inhibiting VKDPs and functions involved in vascular protection.”
https://onlinelibrary.wiley.com/doi/10.1002/kjm2.12373 “Statins, vascular calcification, and vitamin K-dependent proteins: Is there a relation?”
All of this study’s measurements were done outside the liver, so Vitamin K deficiency ≈ Vitamin K2 deficiency. The uncited third paper of Vitamin K2 – What can it do? provided evidence for findings of the current study.
Per the third paper, I should have reached a blood serum level Vitamin K2 MK-7 plateau by supplementing for three weeks. We’ll see later this week if an increasing cOC / ucOC ratio had any effect on hypertension.